Insight journal - Technology

Regenerative medicine: recent partnering deal trends

Posted on 24 July 2014

Regenerative medicine has become increasingly popular in recent years, with the number of deals announced growing steadily.

According to Current Agreements life science deals and alliance database, there have been over 700 regenerative medicine / stem cell deals in the last five years alone.

Figure 1: Regenerative medicine and stem cells partnering since 2009









Source: Current Agreements, 2014

Whilst regenerative medicine / stem cells is primarily a biotechnological development, the potential of this approach to treating a number of serious and previously untreatable conditions, has given rise to interest from a number of the top pharmaceutical (big pharma) companies.

A useful means of understanding best practice in regenerative medicine and stem cells dealmaking is to follow the activities and deal terms used by the most active companies in a certain type of deal. Although big pharma companies have shown interest in this technology in the recent past, it is the biotechnology companies who are most active in this field of technology.

The figure below shows the most active dealmakers in regenerative medicine and stem cells partnering since 2009

Figure 2: Most active dealmakers in regenerative medicine and stem cells since 2009











Source: Current Agreements, 2014

The therapy areas where regenerative medicine / stem cell deals are signed are focused around a large number of main target areas. The main area is oncology (204 deals), cardiovascular (104 deals), CNS(93 deals), hospital care (87 deals) and hospital care diseases (87 deals) all prominent since 2009.

Figure 3: Top therapy areas for regenerative medicine and stem cells partnering since 2009




















Source: Current Agreements, 2014

As an emerging and exciting new area for therapeutic intervention, regenerative medicine / stem cell deals can have a high headline value, where rewards can exceed a billion dollars should products reach the market.

Figure 4: Selected deals for regenerative medicine and stem cells partnering since 2009




















Source: Current Agreements, 2014

The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides full details of over 700 regenerative medicine / stem cell deals announced since 2009 and includes average deal terms including headline, upfront, milestone and royalty rates. In addition the report provides details of deals broken down by deal type, therapy focus company A-Z. More details here.

It is expected that regenerative medicine and stem cells deals will continue in popularity in the coming months and years, as this emerging approach to therapeutic intervention becomes more widespread.

However, the future of regenerative medicine treatment intervention has many hurdles to surmount, not least the achievement of the first widespread regenerative medicine treatment to receive regulatory approval and subsequent use without unforeseen side effects, which due to the nature of the technology may take years to full understand.


Regenerative medicine is the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function - for a full definition – view our regenerative medicine glossary entry.

Stem cells Stem cells are cells found in all multicellular organisms, that can divide and differentiate into diverse specialized cell types and can self-renew to produce more stem cells – for a full definition – view our stem cells glossary entry.


The above information has been abstracted from the following resources:

Steve Poile



Read: more regenerative medicine deals in pharma, biotech, life science partnering deal news, insights and glossary

Read: more stem cell deals in pharma, biotech, life science partnering deal news, insights and glossary

View: glossary definition for regenerative medicine

View: glossary definition for stem cells

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Print Friendly, PDF & Email

Leave a Reply